The United Arab Emirates (UAE) is innovating cancer care with its first programme using TIL (tumour-infiltrating lymphocyte) therapy. This programme represents a turning point in the application of advanced, personalised immunotherapy for patients with tumours that have not responded to standard therapies. A new frontier in treatment In this programme, lymphocyte immune cells are isolated directly from a patient’s tumour …
